
On June 4, 2026, the Supreme Court ruled 9-0 for Hikma in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889.[1][2] The Court reversed the Federal Circuit and sent the case back for further proceedings.[3] It held that Amarin did not plausibly allege that Hikma actively induced infringement of Amarin’s patents.[2]
The ruling affects generic companies, brand companies, and biosimilar developers. All three groups work with skinny labels. A skinny label is the generic drug label that remains after a company removes a use that a patent still protects. This guide explains the statute, the Orange Book mechanics, the key cases, and a five-step carve-out process.
The Short Answer: What Is Skinny Labeling?
Skinny labeling is a Hatch-Waxman Act practice. A generic company asks FDA to approve its drug for only the uses that no patent protects. The company leaves the patented use out of its labeling. It tells FDA that the listed method-of-use patent does not claim the uses that remain.[4]
What Is a Section viii Statement?
A section viii statement is the formal filing that makes a carve-out possible. It sits in 21 U.S.C. 355(j)(2)(A)(viii).[5] The filer states that the method-of-use patent does not claim a use for which the filer seeks approval.[5] Congress created the option in the Hatch-Waxman Act of 1984.[4]
Why Do Generic Companies Carve Out Indications?
A brand drug often has several approved uses. A method-of-use patent may cover only one of them. A carve-out lets the generic company sell the product for the free uses while the patent runs.[4] The generic company does not need to win a patent challenge to enter the market for those uses.
The route has a cost. The carved-out label must omit the protected use, and the company must avoid conduct that encourages the protected use. Two appellate cases, GSK v. Teva and Amarin v. Hikma, tested where that line sits.
The Six Findings That Matter
- The Supreme Court decided Hikma v. Amarin on June 4, 2026. The vote was unanimous, and Justice Jackson wrote the opinion.[2][3]
- A skinny label that follows FDA rules, plus calling the product a “generic version” and citing the brand’s sales, did not plausibly plead active inducement in Hikma.[6][7]
- The GSK v. Teva jury awarded $234 million in lost profits and $1.4 million in reasonable royalty damages on carvedilol. The calculated total is $235.4 million.[8]
- From FDA approval of Hikma’s ANDA on May 21, 2020 to the Supreme Court decision on June 4, 2026, 2,205 days passed. That is 6.04 years (our calculation).[9][1]
- A section viii statement does not delay FDA’s ability to approve an ANDA. It also earns no 180-day exclusivity.[4][10]
- The Supreme Court decided Caraco v. Novo Nordisk on April 17, 2012, and held that a generic company can use a statutory counterclaim to force correction of an inaccurate use code.[11]
Methodology: How We Built the Timelines and Calculations
What Data Did We Analyze?
We reviewed the Supreme Court opinion in Hikma, the Federal Circuit’s 2024 opinion in the same case, the Supreme Court’s 2012 Caraco opinion, and reported summaries of the GSK v. Teva record. We added a Congressional Research Service report, FDA-related regulatory text, law firm analyses, and news of FTC action. The period runs from the Hatch-Waxman Act in 1984 to June 2026.
We counted each case once under its lead caption. We included an event only if a source gave a date, or at least a month and year. We calculated day counts as the difference between two calendar dates. We calculated years as days divided by 365.25. Any figure that comes from these steps carries the label “our calculation” or “analysis.”
What Are the Limits of This Analysis?
This article does not count section viii ANDAs. The sources we reviewed give no count. Some quotations from the 2026 opinion come from law firm summaries, and readers should check them against the opinion before they rely on them. Some dates, such as the November 2020 Hikma launch, are known only to the month. This article is information, not legal advice.
How Does Section viii Work Under the Hatch-Waxman Act?
Section viii works when some approved uses of a brand drug are patented and others are not. The generic filer seeks approval only for the unpatented uses. The generic label then omits the sections tied to the patented use.[4]
What Does the Statute Require?
The ANDA must contain a statement that the method-of-use patent does not claim the use for which the applicant seeks approval.[5] The patent must be a method-of-use patent. The brand company must have listed it with FDA. The statement must be accurate, because the generic filer takes on the risk if a court later reads the patent more broadly.
What Does FDA’s Labeling Rule Say?
ANDA labeling must generally match the labeling of the reference listed drug under 21 CFR 314.94(a)(8)(iv).[12] A carve-out is a recognized exception. The generic label omits the protected use and the sections that relate to it.[4]
FDA has also said it can approve ANDAs with broad, general indications that partly overlap a protected use. The condition is that the label omits every express reference to the protected use.[13]
Section viii vs. Paragraph IV: What Is the Difference?
| Feature | Paragraph IV certification | Section viii statement | Source |
|---|---|---|---|
| What the filer says | The patent is invalid or not infringed | The patent does not claim the use for which approval is sought | [10][4] |
| Notice to the brand company | Required | Not required | [10] |
| 30-month stay | Can follow a suit by the brand | Does not delay FDA approval | [10][4] |
| 180-day exclusivity | Available to a qualifying first filer | Not available | [10] |
| Label | Same as the brand label | Brand label without the carved-out use | [4] |
Does a Section viii Statement Trigger a 30-Month Stay?
No. CRS states the rule in one sentence: “Unlike a paragraph IV certification, a section viii statement does not delay FDA’s ability to approve the ANDA.”[4] The brand company can still sue for infringement after launch. That is the route GSK and Amarin took.
Does a Section viii Filer Earn 180-Day Exclusivity?
No. The 180-day period belongs to qualifying Paragraph IV filers.[10] A section viii filer enters the market without that reward. The filer gets speed and certainty about the patent challenge, and gives up exclusivity.
Orange Book Use Codes: Why They Decide the Carve-Out
What Is an Orange Book Use Code?
FDA regulations require a brand company to describe any method-of-use patent it lists. The Supreme Court wrote that “That description is known as a use code.”[11] The use code tells a generic company which use the patent claims. The generic company then knows what to remove from its label.
The brand company writes the code. One source reports a 240-word limit on use codes and says FDA treats its own role in patent listing as ministerial.[10] FDA therefore does not test whether a code is accurate.
How Can a Generic Company Challenge a Use Code? Caraco v. Novo Nordisk
A generic company can file a counterclaim. Congress created the counterclaim in the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. It lets a generic company ask a court to order the brand to correct or delete patent information.[11]
What Were the Facts in Caraco?
The drug was repaglinide, which Novo Nordisk sells as Prandin. The compound patent, the ‘035 patent, expired in 2009. The ‘358 patent is a method-of-use patent that ran until 2018. It claims repaglinide used with metformin.[11]
Novo first described the ‘358 patent in the use code as “Use of repaglinide in combination with metformin to lower blood glucose.” It later changed the code to “A method for improving glycemic control in adults with type 2 diabetes.”[11] The broader code blocked Caraco’s carve-out, because it described the patent as covering nearly every use.
What Did the Supreme Court Hold in Caraco?
Justice Kagan wrote for a unanimous Court on April 17, 2012. The Court held that a generic company may use the counterclaim to force correction of a use code that wrongly describes the patent.[11] The Court granted review on June 27, 2011 and heard argument on December 5, 2011.[11]
Analysis: From cert grant to decision, Caraco took 295 days (our calculation). From argument to decision, it took 134 days.
Is the FTC Challenging Orange Book Patent Listings?
Yes. In November 2023, the FTC began challenging improper Orange Book listings as an unfair method of competition under Section 5 of the FTC Act.[14] In May 2024, it sent 10 more warning letters, which brought the total of challenged listings to about 400.[14]
On May 21, 2025, the FTC sent seven letters. They targeted about 200 listings across 17 NDAs. The patents covered inhalers and other drug delivery devices.[14] Those challenges address listing accuracy. The use-code counterclaim in Caraco addresses a different problem, which is the description of a listed method-of-use patent.
How to Carve Out a Patented Indication: A Five-Step Process
The process below is a workflow for a generic regulatory and patent team. It draws on the statute, the regulation, and the cases in this article. A patent attorney must review each step for the specific product.
Step 1: Map Every Listed Patent and Use Code
Pull the Orange Book listing for the reference listed drug. Record each method-of-use patent, its expiration date, and its use code. Record which patents cover which approved indication. A patent family tracker, such as DrugPatentWatch, can speed this work. The Orange Book remains the primary source.[15]
Step 2: Compare Each Use Code With the Brand Label
Place each use code next to the brand’s approved indications and label sections. Look for overlap. If the code is broader than the patent claim, a Caraco counterclaim may be available.[11] If the brand indication is broad and the protected use is narrow, consider FDA’s stated position on partial overlap.[13]
Step 3: Draft the Carve-Out Label
Start from the brand label. Remove the protected indication and the sections tied to it.[4] Keep the information that FDA rules require you to keep. In Hikma, the Supreme Court treated the retention of clinical study information as consistent with the rule that the generic label must mirror the brand label apart from the carved-out use.[6]
Step 4: File the Section viii Statement
Include the statement in the ANDA. Teva’s path shows the mechanics. Teva first filed a Paragraph IV certification on the ‘069 patent in 2002, then amended it to a section viii statement in August 2007. FDA approved the ANDA in September 2007.[8] The amendment shows that a generic company can change its certification strategy while an ANDA is pending.
Step 5: Control Every Launch Communication
Review product catalogs, press releases, websites, and investor materials before launch. In GSK v. Teva, the Federal Circuit looked at press releases and catalogs that called Teva’s product an AB-rated equivalent of Coreg.[16] In Hikma, the Supreme Court held that comparable language did not plausibly plead inducement.[7] The Federal Circuit had also noted in 2024 that “clarity and consistency in a generic manufacturer’s communications” may help avoid liability.[9]
What Is Induced Infringement and Why Does It Threaten Skinny Labels?
A brand company cannot sue a section viii generic for direct infringement of a method-of-use patent. The generic company does not perform the method. The brand company instead alleges that the generic company induced doctors or patients to perform it. That claim arises under 35 U.S.C. 271(b).
What Must a Patent Owner Prove for Active Inducement?
Induced infringement requires at least one direct infringer. It requires that the inducer knew the acts infringe. It also requires active steps to encourage the infringement.[17] Ordinary acts that come with distributing a product are not enough.[17]
Which Cases Before GSK Tested Label-Based Infringement?
In Warner-Lambert v. Apotex, a gabapentin generic won approval only for adult seizures. The Federal Circuit held that off-label neurodegenerative use did not establish infringement under 35 U.S.C. 271(e)(2).[13] In Bayer v. Lupin, the court found that the Yasmin generic label did not recommend the claimed combination of effects.[13]
In Hospira v. Burwell, FDA approved generic Precedex through section viii statements despite overlap concerns. The district court upheld FDA’s decision, and the parties settled before appeal.[13] These cases dealt with approval and label content. GSK and Amarin dealt with conduct after launch.
GSK v. Teva: How a Carvedilol Skinny Label Led to a $235 Million Verdict
What Were the Facts in GSK v. Teva?
FDA approved Coreg (carvedilol) in May 1997 for congestive heart failure.[8] GSK held U.S. Patent No. RE40,000, which was reissued in January 2008 from U.S. Patent No. 5,760,069. It expired in June 2015.[8] The patent covered the heart failure use.
Teva filed its ANDA in March 2002. In August 2007, Teva amended its certification to a section viii statement and removed the heart failure indication. FDA approved the ANDA in September 2007, and Teva launched that month.[8]
The skinny-label period ran from January 2008 to April 2011. In April 2011, Teva added the heart failure indication back. The full-label period ran from May 2011 to June 2015.[8] GSK sued in the District of Delaware in 2014.[18]
Analysis: The skinny-label period lasted 40 months. The full-label period lasted 50 months. Together they cover 90 months, and the $235.4 million award works out to about $2.6 million per month if spread evenly. The jury did not allocate damages that way. We show the figure only to give scale.
What Did the Federal Circuit Decide in GSK v. Teva?
After a seven-day trial, the jury found for GSK.[8] Judge Stark then granted judgment as a matter of law for Teva in 2018.[8] On October 2, 2020, a Federal Circuit panel of Judges Prost, Newman, and Moore vacated that ruling. Judge Newman wrote the opinion, and Chief Judge Prost dissented.[16]
The panel pointed to Teva’s press releases, which called its product an AB-rated equivalent of Coreg. It pointed to Teva’s product catalogs, which compared carvedilol with Coreg. It also pointed to Teva’s 2011 label amendment.[16] The court issued a second opinion on rehearing on August 5, 2021, with the same outcome. Judge Prost dissented again.[18]
Why Did the Supreme Court Deny Review in GSK v. Teva?
The Supreme Court denied Teva’s petition on May 15, 2023.[18] Teva had filed it on July 11, 2022.[18] The sources I reviewed do not explain why the Court denied it, because the Court did not write an opinion on the denial.
What Was the Solicitor General’s Position?
The Solicitor General urged the Court to grant review. The government argued that the Federal Circuit’s decision threatened the availability of lower-cost generic drugs.[18] The Court denied review anyway.
What Did the Dissent Say?
Chief Judge Prost argued that the majority’s holding “nullifies Congress’s statutory provision for skinny labels.”[16] She argued that no Teva communication encouraged doctors to use generic carvedilol for the patented method.[16] Six years after the 2020 opinion, the Supreme Court’s 2026 decision rejected the approach she criticized, as we describe below.
Amarin v. Hikma: The Vascepa Skinny Label Case
What Were the Facts in Amarin v. Hikma?
Amarin sells Vascepa (icosapent ethyl). FDA approved it for severe hypertriglyceridemia (the SH indication) in 2012. In 2019, FDA approved it to reduce cardiovascular risk in certain statin-taking patients (the CV indication).[9] The CV indication accounts for more than 75% of Vascepa sales.[17]
The CV indication accounts for over 75% of Vascepa sales, according to WilmerHale’s June 10, 2026 client alert on the Hikma decision.[17]
Hikma submitted its ANDA in 2016. When FDA approved the CV indication in 2019, Hikma’s application was still pending. Hikma chose a section viii carve-out over a label that matched Vascepa’s.[9] FDA approved Hikma’s ANDA, including its skinny label, on May 21, 2020.[9] The approval carried an AB rating.[6]
Hikma launched in November 2020. Amarin sued less than a month later.[9] Amarin asserted U.S. Patents 9,700,537 and 10,568,861, both directed to the CV use.[9]
What Did the Federal Circuit Decide in 2024?
The district court dismissed Amarin’s complaint in 2022.[17] On June 25, 2024, the Federal Circuit reversed. Judge Lourie wrote the opinion for a panel that included Chief Judge Moore and District Judge Albright, sitting by designation.[9]
The court wrote: “we hold that Amarin has plausibly pleaded that Hikma has induced infringement of the asserted patents.”[9] It considered the label together with Hikma’s press releases and website.[9] The allegations included a press release that called the product a “generic version” without noting its narrower indication. Another release gave Amarin’s total sales, not sales by indication. The website placed the product in a broader therapeutic category.[19]
What Did the Supreme Court Decide in 2026?
The Court granted review on January 16, 2026.[20] The petition raised two questions. The first asked whether calling a carved-out product a “generic version” and citing brand sales data suffices to plead inducement. The second asked whether a complaint states a claim when it alleges no instruction or statement that encourages the patented use.[19] At the cert stage, the Solicitor General generally sided with Hikma.[19]
The Court decided the case on June 4, 2026. It reversed the Federal Circuit and remanded.[3] Amarin’s complaint did not state “more than a sheer possibility that Hikma actively induced infringement of Amarin’s CV-indication patents.”[7]
The Court Asks Whether the Defendant Actively Encouraged Infringement
The Court framed the issue this way: “the key question is whether a defendant actively encouraged infringement through its statements.”[7] It rejected the Federal Circuit’s focus on whether a doctor could plausibly read a statement as encouragement.[6] As quoted in a Foley Hoag alert, the Court wrote that “statements designed to stimulate others form a narrower category than statements that could stimulate others.”[21]
The Court did not require express encouragement. It wrote that “[a] defendant can achieve active inducement through implicit encouragement.”[7] The encouragement must still be affirmative and clear to its audience.[6]
The Obvious Alternative Explanation
Several statements had an innocent source. The label kept clinical study information because the law requires the generic label to mirror the brand label apart from the carved-out use. The phrase “generic Vascepa” reflected normal industry practice.[6] The Court called these an “obvious alternative explanation” for the statements.[7]
Omissions Do Not Count as Inducement
Amarin pointed to what Hikma left out, including the CV limitation of use and any note that the product had only the SH approval. The Court called these “mere omissions, inactions, or nonfeasance.”[17][21] They cannot alone allege active inducement.[6]
The Court also treated vague statements as insufficient. The leaflet’s side-effect warnings, the website’s broad category description, and investor press releases with sales figures fell in that group.[6] The Court reasoned that holding otherwise would put “generic manufacturers between a rock and a hard place.”[21]
GSK v. Teva vs. Amarin v. Hikma: How Do the Cases Compare?
| Item | GSK v. Teva | Amarin v. Hikma | Source |
|---|---|---|---|
| Brand drug | Coreg (carvedilol) | Vascepa (icosapent ethyl) | [8][9] |
| Carved-out use | Congestive heart failure | Cardiovascular risk reduction | [8][9] |
| Generic launch | September 2007 | November 2020 | [8][9] |
| Stage of the key ruling | Jury verdict, then post-trial | Motion to dismiss | [8][17] |
| Result in district court | $234 million lost profits plus $1.4 million royalty; later set aside by the judge | Complaint dismissed in 2022 | [8][17] |
| Federal Circuit ruling | October 2, 2020, and August 5, 2021 | June 25, 2024 | [16][18][9] |
| Supreme Court action | Cert denied May 15, 2023 | Reversed June 4, 2026 | [18][3] |
| Statements at issue | Press releases, catalogs, and a 2011 full label | Press releases, website, and the skinny label | [16][19] |
Analysis: The two cases differ in procedure. GSK reached a jury. Amarin never got past the pleading. Hikma still matters to GSK-type claims, because the Court rejected the Federal Circuit approach that GSK exemplified.[17]
Skinny Label Timeline: Key Events From 1984 to 2026
| Date | Event | Source |
|---|---|---|
| 1984 | Hatch-Waxman Act creates the ANDA pathway and the section viii option | [4] |
| 2003 | Medicare Prescription Drug, Improvement, and Modernization Act creates the counterclaim to correct patent information | [4] |
| September 2007 | FDA approves Teva’s carvedilol ANDA; Teva launches | [8] |
| January 2008 | RE40,000 reissues | [8] |
| April 2011 | Teva adds the heart failure indication back | [8] |
| April 17, 2012 | Supreme Court decides Caraco v. Novo Nordisk | [11] |
| 2014 | GSK sues Teva in the District of Delaware | [18] |
| June 2015 | RE40,000 expires | [8] |
| 2018 | District court sets aside the GSK jury award | [8] |
| May 21, 2020 | FDA approves Hikma’s icosapent ethyl ANDA | [9] |
| October 2, 2020 | Federal Circuit vacates the GSK judgment as a matter of law | [16] |
| November 2020 | Hikma launches; Amarin sues within a month | [9] |
| August 5, 2021 | Federal Circuit issues its opinion on rehearing in GSK | [18] |
| May 15, 2023 | Supreme Court denies cert in Teva v. GSK | [18] |
| June 25, 2024 | Federal Circuit reverses dismissal in Amarin v. Hikma | [9] |
| January 16, 2026 | Supreme Court grants cert in Hikma v. Amarin | [20] |
| June 4, 2026 | Supreme Court reverses, 9-0 | [1][2] |
What Do the Dates Show About Skinny-Label Litigation Length?
Analysis: All figures in this section are our calculations from the dates above. Teva’s generic launched in September 2007. The Supreme Court denied review in May 2023. That interval is 5,735 days, or 15.7 years, counted from September 1, 2007.
The Hikma case moved faster at the Supreme Court. The Federal Circuit ruled on June 25, 2024. The Supreme Court ruled 709 days later. The Court took 139 days from its grant of review to its decision. In total, 2,205 days passed between FDA approval of Hikma’s ANDA and the ruling.
A skinny label does not end disputes. It moves the dispute from the FDA approval stage to the court stage. A generic company should plan for years of possible litigation, even with a compliant label.
What Does Hikma v. Amarin Mean for Generics, Brands, and Biosimilars?
What This Means for Generic Manufacturers
The skinny-label route is more secure than it was after GSK. A compliant label plus routine statements is unlikely to meet the “active steps” test.[21] The pleading stage is the focus of the ruling. It does not give blanket immunity.[21]
Public-facing material still matters. Communications that aim to drive prescribing for a patented use could support liability, even without naming that use.[21] Marketing, investor communications, and website category descriptions need review against the Court’s framework.[21]
What This Means for Brand Manufacturers
Inducement claims built from a generic’s label, press releases, and ordinary website content are harder to plead.[21] Brand companies should investigate a generic company’s public statements early. They should also coordinate label updates with patent strategy, especially where an unpatented use drives sales.[7]
Companies that ran post-approval trials to win a new indication may need other tools to protect a method-of-use patent.[21] Monitoring generic promotion for affirmative encouragement becomes more important.[21]
What This Means for Biosimilar Developers
The BPCIA pathway has its own carve-out logic. FDA’s February 2020 draft guidance says a biosimilar may generally be licensed for fewer than all of the reference product’s licensed conditions of use.[22] Exclusivity and patents can each drive that choice.[22]
Orphan and Pediatric Exclusivity Carve-Outs
FDA cannot license a biosimilar for a use that orphan-drug or pediatric exclusivity protects until that exclusivity expires. It can license the biosimilar for the other uses. The applicant can later file a supplement to add the use.[22]
Patent-Based Carve-Outs
The BPCIA does not limit FDA’s ability to act on an application for a use that a patent covers. An applicant that wants approval after patent expiry can ask FDA not to act before a stated date.[22] Whether Hikma’s inducement reasoning applies to biosimilars is not settled in the sources I reviewed. The Foley Hoag alert notes that the Court relied on inducement cases from outside patent law, which suggests the standard reaches beyond Hatch-Waxman disputes.[21]
Why Does an AB Rating Create a Leakage Problem for Carved-Out Uses?
A section viii generic receives the same “A” rating whether or not it carves out every use. That rating can allow state-law automatic substitution, even for a carved-out use.[10] Pharmacists could dispense the generic for the patented indication, often automatically under some state laws.[19]
Analysis: This leakage is why brand companies sue. A generic company does not need to market the patented use for sales to reach it. Hikma suggests that, at the pleading stage, the leakage alone does not show inducement.
A Taxonomy of Skinny-Label Risk (Original Framework)
This framework is ours. It is not an FDA or industry classification. It sorts a generic company’s record by what the company said and did, because the cases turned on that record. We place the cases we reviewed into the types, and we state where the sources leave a question open.
What Are the Five Skinny-Label Record Types?
Type 1: Silent Carve-Out
The label omits the protected use. The company makes no statements about the brand or the carved-out use. Hikma’s reasoning treats omissions as insufficient on their own.[6]
Type 2: Equivalence Statements
The company calls its product a generic version or an AB-rated equivalent. The Federal Circuit treated such statements as evidence in GSK.[16] The Supreme Court held that comparable statements did not plausibly plead inducement in Hikma.[7][6]
Type 3: Combined-Sales Statements
The company cites the brand’s total sales, not sales by indication. Amarin alleged this in a press release.[19] The Court found investor-facing sales figures too vague.[6]
Type 4: Full-Label Conversion
The company adds the protected use back to its label. Teva did this in April 2011, and the jury found for GSK for the period that followed.[8][18] The sources I reviewed describe Hikma as a carved-out label case. Analysis: A company that restores the protected use has a different record, and Hikma may not help it.
Type 5: Targeted Promotion
The company designs statements to encourage the protected use. No case in this article presents that record. The Court left room for it, because inducement can rest on implicit encouragement that is affirmative and clear.[7][6]
| Type | What the record shows | Case signal | Source |
|---|---|---|---|
| 1. Silent carve-out | Label omission only | Omissions insufficient alone | [6] |
| 2. Equivalence statements | “Generic version” or AB-rated language | Evidence in GSK; insufficient in Hikma | [16][7] |
| 3. Combined-sales statements | Total brand sales cited | Too vague in Hikma | [6] |
| 4. Full-label conversion | Protected use added back | Jury verdict in GSK | [8][18] |
| 5. Targeted promotion | Statements aimed at the protected use | Not tested here; implicit encouragement can suffice | [7] |
Scenario Analysis: Four Brand Strategies Against a Method-of-Use Patent
These scenarios are analysis, not forecasts. Each rests on a stated assumption that comes from the cases above.
| Scenario | Assumption | Likely generic path | What to watch |
|---|---|---|---|
| A. Narrow code | The use code matches the patent claim | Generic carves out the claimed use and files section viii | Launch communications |
| B. Broad code | The use code covers more than the patent claims | Generic files a counterclaim to correct the code, as in Caraco | Court ruling on code accuracy[11] |
| C. New indication after ANDA filing | FDA approves a patented use while the ANDA is pending | Generic chooses a carve-out over a matching label, as Hikma did in 2019 and 2020 | Whether the label diverges from the brand[9] |
| D. Patent covers the main revenue use | The patented use drives most sales, as with Vascepa’s CV use | Generic launches on the free use; substitution may carry volume to the patented use | Pharmacy substitution and inducement pleading[17][10] |
Scenario D carries heavy commercial pressure. The Vascepa CV indication accounts for more than 75% of sales.[17] A brand in that position relies on an inducement claim, and Hikma makes that claim harder to plead.[21]
Skinny Labels, Big Savings Act: What Is Congress Considering?
Congress has a bill that would write a safe harbor into law. Senator Hickenlooper introduced S. 43, the Skinny Labels, Big Savings Act, on January 9, 2025. The Senate referred it to the Judiciary Committee. H.R. 6485 is an identical House bill.[23]
The bill would protect generic or biosimilar makers that seek or obtain approval for a skinny label. It covers marketing a product with an approved skinny label. It also covers describing the product as a generic or therapeutically equivalent product. It extends the same protection to similar actions under the Public Health Service Act.[23]
The bill responds to GSK v. Teva.[23] The tracker page I reviewed shows no markup or passage. Readers should check congress.gov for the current status. An earlier bill, S. 1128 in the 118th Congress, would have created a cause of action to correct Orange Book patent information.[4]
How Can DrugPatentWatch Help Review a Carve-Out?
DrugPatentWatch compiles drug patent listings, expiration dates, and patent litigation records for drug products.[15] A carve-out review starts with those facts. Which method-of-use patents does the brand list? When does each expire? Has anyone challenged them in court?
The platform gives context for the Orange Book data. It does not replace the Orange Book, the patent documents, or the court record. A team should confirm every patent number, expiration date, and use code against FDA and USPTO sources before it files a section viii statement.
Key Takeaways
- A skinny label omits a patented use. The generic filer supports it with a section viii statement under 21 U.S.C. 355(j)(2)(A)(viii).[5]
- A section viii statement does not delay FDA approval. It also earns no 180-day exclusivity.[4][10]
- Use codes decide what a generic company can carve out. Caraco lets generic companies challenge an inaccurate code through a counterclaim.[11]
- GSK v. Teva produced a $234 million lost-profits award and a $1.4 million royalty award. The Supreme Court denied review on May 15, 2023.[8][18]
- Hikma v. Amarin, decided June 4, 2026, held that Amarin did not plausibly plead active inducement.[2]
- The Court asked whether the defendant actively encouraged infringement. It did not ask whether a doctor could read a statement that way.[7][6]
- The ruling concerns the pleading stage. Public statements can still create liability if they are designed to encourage the patented use.[21]
- Biosimilar developers can seek licensure for fewer than all of a reference product’s conditions of use.[22]
FAQ
Can a Generic Company Add a Carved-Out Use Back to Its Label Later?
Yes, a label can change, but the change carries risk. Teva added the heart failure indication back in April 2011, while RE40,000 ran until June 2015.[8] The jury later found inducement for the full-label period as well as the skinny-label period.[18]
Does a Skinny Label Protect a Generic Company From Every Infringement Suit?
No. Hikma decided a pleading question. The ruling does not grant blanket immunity to generic companies.[21] A complaint that alleges clear, affirmative encouragement of the patented use can still proceed.[6]
Does Calling a Product “Generic Equivalent” Create Inducement Liability?
Not by itself, according to the Supreme Court’s reasoning in Hikma. The Court treated “generic Vascepa” as normal industry practice.[6] It saw an obvious alternative explanation for the phrase.[7]
Can a Pharmacist Fill a Skinny-Label Prescription for the Carved-Out Use?
It can happen. A section viii generic receives the same A rating, and some state laws allow automatic substitution.[10] The Hikma record noted that pharmacists could dispense the generic for the patented indication.[19]
Who Writes an Orange Book Use Code, and Does FDA Check It?
The brand company writes the use code. One source says FDA regards its listing role as ministerial.[10] A generic company that disagrees with a code can file a counterclaim to correct or delete the patent information.[11]
What Did Caraco v. Novo Nordisk Change?
Caraco confirmed that the statutory counterclaim reaches a use code that wrongly describes a patent. Before that, a broad code could block a carve-out. The Court decided the case on April 17, 2012, in a unanimous opinion by Justice Kagan.[11]
Can Biosimilars Use a Skinny Label?
Biosimilars follow a different statute, the BPCIA, but the idea is similar. FDA’s 2020 draft guidance says a biosimilar may generally be licensed for fewer than all conditions of use. Orphan and pediatric exclusivity block licensure for a protected use until the exclusivity ends.[22]
What Position Did the Solicitor General Take in the Skinny-Label Cases?
In GSK v. Teva, the Solicitor General urged the Court to grant review.[18] In Hikma, the Solicitor General generally sided with Hikma at the cert stage.[19] In both cases the government’s concern was the availability of lower-cost generic drugs.[18]
Is There a Law That Would Create a Statutory Safe Harbor for Skinny Labels?
Not yet. S. 43 and H.R. 6485, the Skinny Labels, Big Savings Act, would create one. S. 43 was referred to the Senate Judiciary Committee on January 9, 2025.[23] The tracker page I reviewed showed no markup or passage.
What Should a Brand Company Monitor After Hikma?
A brand company should monitor generic promotion for affirmative encouragement of the patented use.[21] It should also coordinate label updates with patent strategy, because an unpatented use can drive sales.[7] Early investigation of a generic company’s public statements is part of that work.[7]
References
- [1] Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889 (U.S. June 4, 2026). Supreme Court of the United States. https://www.supremecourt.gov/opinions/25pdf/24-889_5i36.pdf
- [2] American Intellectual Property Law Association. (2026, June 4). Supreme Court issues unanimous decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. AIPLA. https://www.aipla.org/detail/news/2026/06/04/supreme-court-issues-unanimous-decision-in-hikma-pharmaceuticals-usa-inc.-v.-amarin-pharma–inc
- [3] Fed Circuit Blog. (2026, June 4). Breaking news: Supreme Court reverses Federal Circuit’s holding on skinny labeling and inducement of patent infringement. https://fedcircuitblog.com/2026/06/04/breaking-news-supreme-court-reverses-federal-circuits-holding-on-skinny-labeling-and-inducement-of-patent-infringement/
- [4] Congressional Research Service. (2026). “Skinny labels” for generic drugs under Hatch-Waxman (CRS In Focus IF12700). https://www.everycrsreport.com/reports/IF12700.html
- [5] Generic drugs; patent certifications and statements, 21 U.S.C. § 355(j)(2)(A)(viii). https://www.law.cornell.edu/uscode/text/21/355
- [6] Proskauer Rose LLP. (2026). Supreme Court reverses Federal Circuit in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. https://www.proskauer.com/alert/supreme-court-reverses-federal-circuit-in-hikma
- [7] Choate, Hall & Stewart LLP. (2026). Hikma v. Amarin: Supreme Court unanimously rejects induced infringement claims in generic “skinny label” case. https://www.choate.com/insights/hikma-v-amarin-supreme-court-unanimously-rejects-induced-infringement-claims-in-generic-skinny-label-case/
- [8] Orange Book Blog. (2018, April 1). GlaxoSmithKline v. Teva, No. 14-878-LPS-CJB (D. Del.). https://orangebookblog.com/2018/04/01/judge-stark-d-del-holds-generic-label-including-patented-indication-insufficient-to-prove-inducement/
- [9] Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., No. 2023-1169 (Fed. Cir. June 25, 2024). https://www.cafc.uscourts.gov/opinions-orders/23-1169.OPINION.6-25-2024_2339226.pdf
- [10] CRA International. (n.d.). CRA insights: Skinny labeling. https://media.crai.com/wp-content/uploads/2020/09/19110704/CRA-Insights-Skinny-labeling.pdf
- [11] Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S, 566 U.S. 399 (2012). https://supreme.justia.com/cases/federal/us/566/399/
- [12] Abbreviated new drug applications, 21 C.F.R. § 314.94. https://www.law.cornell.edu/cfr/text/21/314.94
- [13] Shook, Hardy & Bacon L.L.P. (n.d.). Skinny labeling (Food and Drug Law Institute). https://www.shb.com/-/media/files/professionals/y/yuephdherman/skinny-labeling-fdli.pdf
- [14] IPWatchdog. (2025, May 22). FTC renews campaign to remove “junk” inhaler and device patents from Orange Book listings. https://ipwatchdog.com/2025/05/22/ftc-renews-campaign-remove-junk-inhaler-device-patents-orange-book-listings/
- [15] DrugPatentWatch. (n.d.). DrugPatentWatch. https://www.drugpatentwatch.com/
- [16] Robins Kaplan LLP. (2021). GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. Generically Speaking, Winter 2021. https://robinskaplan.com/resources/legal-updates/generically-speaking-hatch-waxman-bulletin/2021/generically-speaking-winter-2021/glaxosmithkline-llc-v-teva-pharms-usa-inc
- [17] WilmerHale. (2026, June 10). Supreme Court clarifies pleading standard for induced infringement in Hikma v. Amarin. https://www.wilmerhale.com/en/insights/client-alerts/20260610-supreme-court-clarifies-pleading-standard-for-induced-infringement-in-hikma-v-amarin
- [18] A&O Shearman. (2023). SCOTUS denies cert in skinny label appeal from the Federal Circuit. https://www.aoshearman.com/en/insights/ao-shearman-on-life-sciences/scotus-denies-cert-in-skinny-label-appeal-from-the-federal-circuit
- [19] Morrison & Foerster LLP. (2026, January 20). Supreme Court takes up Hikma v. Amarin. https://www.mofo.com/pdf/resources/insights/260120-supreme-court-takes-up-hikma-v-amarin
- [20] Duane Morris LLP. (2026, January 21). U.S. Supreme Court grants certiorari in Hikma v. Amarin, placing “skinny label” inducement in focus. https://blogs.duanemorris.com/lifescienceslaw/2026/01/21/us-supreme-court-grants-certiorari-in-hikma-v-amarin-placing-skinny-label-inducement-in-focus/
- [21] Foley Hoag LLP. (2026, June). Hikma v. Amarin: It’s not just about skinny labels. https://foleyhoag.com/news-and-insights/publications/alerts-and-updates/2026/june/hikma-v-amarin-it-s-not-just-about-skinny-labels/
- [22] Sterne Kessler. (2020, February 12). FDA issues biosimilar guidance for label carve outs and supplements. https://www.sternekessler.com/news-insights/client-alerts/fda-issues-biosimilar-guidance-label-carve-outs-and-supplements/
- [23] Legilist. (n.d.). S. 43: Skinny Labels, Big Savings Act (119th Congress). https://legilist.com/bill/119/s/43


























